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OBJECTIVE: Evidence concerning the relationship between
medical-care costs and tumor histology among advanced-staged
NSCLC patients is lacking. The purpose of this analysis was to
identify costs associated with ﬁrst-line chemotherapy treatment
and total lifetime medical-care costs by tumor histology among
elderly Stage IIIB/IV NSCLC patients treated with commonly
used doublet chemotherapy regimens. METHODS: Study
patients included those aged 65 years and older who were diag-
nosed with Stage IIIB/IV NSCLC in a SEER cancer registry
between 1997 and 2002 and who received ﬁrst-line treatment
with a commonly used doublet regimen. Study patients were
followed in the SEER-Medicare database to evaluate costs while
on ﬁrst-line chemotherapy treatment as well as lifetime medical-
care costs by histology for commonly used doublets. Pairwise
comparisons of costs estimated using non-parametric bootstrap
methodology were generated for treatment comparisons. Esti-
mated differences in mean costs, adjusted for sex, race age,
urban/rural, geographic region, stage, Charlson comorbidity
index and tumor histology are presented. RESULTS: Total life-
time medical-care costs for elderly IIIB/IV patients with squa-
mous cell carcinoma were $51,360, while costs for those with
non-squamous cell carcinoma were $50,905. Costs per month
were $6364 and $6870 respectively, and were dominated by
hospital and physician utilization. Among commonly used dou-
blets, the estimated difference in adjusted mean total costs for
Cisplatin/Carboplatin (P) and a Taxane (T) were signiﬁcantly
higher when compared to P and Gemcitabine (G) (difference
$4816 [$1554–$8101]). Similar ﬁndings were observed for costs
while on ﬁrst-line therapy, (difference $5686 [3738-$7630]
respectively). CONCLUSION: While lifetime medical-care costs
and costs while on ﬁrst-line chemotherapy among treated Stage
IIIB/IV NSCLC patients are substantial, the cost differential
between squamous cell and non-squamous cell carcinoma is
small. Controlling for tumor histology and other factors, patients
treated with a combined platinum and taxane regimen experi-
ence the highest costs.
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OBJECTIVE: Platinum-based chemotherapies have been associ-
ated with debilitating treatment-related complications among
patients with advanced squamous cell carcinoma of the head and
neck (ASCCHN). This study evaluated the incidence and costs of
such complications among ASCCHN patients undergoing radio-
therapy alone versus platinum-based chemoradiotherapy.
METHODS: Using 2000–2006 data from the PharMetrics
Patient-centric Database, this retrospective cohort study mea-
sured clinical practices, incidence rates, and costs of treatment-
related complications including oral complications, dehydration,
infection/fever, fatigue, malnutrition, nausea, neutropenia and
anemia among ASCCHN patients undergoing radiotherapy
alone or platinum-based chemoradiotherapy. Patients were iden-
tiﬁed if they had a SCCHN claim between June 30, 2000 and
December 31, 2005 and an indication of a secondary malignant
neoplasm (both based on ICD-9-CM diagnosis codes). Patients
were assigned to a treatment-based cohort–radiotherapy only or
platinum-based chemo-radiotherapy, and were followed for six
months. RESULTS: We identiﬁed 131 ASCCHN patients treated
with radiotherapy alone and 90 patients treated with chemora-
diotherapy, including 62 with cisplatin plus radiotherapy, 30
with carboplatin plus radiotherapy, and two with cisplatin and
carboplatin plus radiotherapy. Patients undergoing chemo-
radiotherapy were slightly younger than radiotherapy patients
(mean ages: 54.1 and 56.1 years, respectively), were more likely
to be male, and were less healthy, as evidenced by higher
Charlson co-morbidity scores. We found signiﬁcantly (P < 0.001)
higher rates of treatment-related complications among patients
receiving chemo-radiotherapy (87%) compared with patients
receiving only radiotherapy (51%). Mean per-patient costs asso-
ciated with treatment-related complications were $10,632 higher
among chemo-radiotherapy patients compared to radiotherapy
patients (P = 0.002). These costs comprised 18% of total costs
during follow-up for chemo-radiotherapy patients and 9% of
costs for radiotherapy patients. The most expensive complica-
tions were dehydration/electrolyte imbalance and oral complica-
tions. CONCLUSION: Our ﬁndings suggest that the excess
incidence and costs of treatment-related complications associated
with chemo-radiotherapy in ASCCHN are substantial. The emer-
gence of safer treatments may alleviate this cost burden.
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OBJECTIVE: To estimate mean costs per event of the most
common adverse events (AEs) due to treatment of non-small cell
lung cancer (NSCLC) in Mexican patients based on treatment
patterns (TP) and resource utilization. METHODS: Specialists
were invited to participate in a Modiﬁed Delphi Panel to
acknowledge real TP of AEs for patients undergoing NSCLC
treatment such as neutropenia (NP), anemia (AN), thrombocy-
topenia (TC), febrile neutropenia (FN), dyspnea (DS), hypersen-
sitivity (HS), rash (RA), nausea (NS), vomiting (VO), diarrhea
(DR), stomatitis (ST), peripheral neuromotor alterations (PNA),
anorexia (AX) and interstitial lung disease (ILD). Questionnaire
was designed based on experts’ opinion and answered by spe-
cialists, using a nine level Likert scale in order to obtain consen-
sus for the proposed scenarios. Scenarios included drugs use,
percentage of hospitalized patients, hospitalization days and visit
to emergency room, and laboratory/cabinet exams. Afterwards,
an analysis and controlled feedback with a moderated debate
stage took place until consensus achievement (7 approval-
median) for each questionnaire item. Economic analysis was
done under the public sector perspective. Unitary costs were
obtained from the Mexican Institute of Social Security (Diario
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